RegeneRx Enrolls Patients for Dry Eye Trial

The Company expects to complete patient enrollment in August and for the last patient to complete the study in September, with preliminary data from the study scheduled to be available in October 2011.

RegeneRx Biopharmaceuticals, Inc. announced that the first patients have been enrolled to receive RGN-259 or placebo in its 72-patient, Phase 2 clinical trial in patients with dry eye syndrome.

The Company expects to complete patient enrollment in August and for the last patient to complete the study in September, with preliminary data from the study scheduled to be available in October 2011.

The double-masked, placebo-controlled clinical trial will evaluate the safety and efficacy of RGN-259, the Company's proprietary preservative-free eye drops. Patients will receive RGN-259 or placebo twice daily for 30 days. Signs and symptoms of dry eye, such as the degree of ocular surface damage, ocular itching, burning and grittiness, among others, w